Becton, Dickinson and Company $BDX Stock: TD Waterhouse Canada Inc. Raises Holdings

TD Waterhouse Canada Inc. boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 35.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 130,042 shares of the medical instruments supplier’s stock after buying an additional 33,831 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Becton, Dickinson and Company were worth $23,278,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in BDX. BlackRock Inc. bought a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $3,721,533,000. State Street Corp increased its stake in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock worth $2,269,960,000 after purchasing an additional 1,177,256 shares during the last quarter. First Eagle Investment Management LLC raised its holdings in shares of Becton, Dickinson and Company by 15.8% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after purchasing an additional 1,887,224 shares during the period. Auto Owners Insurance Co raised its holdings in shares of Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the period. Finally, Bank of America Corp DE acquired a new stake in Becton, Dickinson and Company in the 2nd quarter valued at about $474,993,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of several recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research note on Monday, July 6th. Barclays initiated coverage on Becton, Dickinson and Company in a research report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective for the company. Finally, Weiss Ratings upgraded Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $185.07.

Becton, Dickinson and Company Trading Down 1.3%

BDX stock opened at $191.34 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The company has a fifty day moving average price of $184.03 and a two-hundred day moving average price of $163.70. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $195.99. The stock has a market cap of $52.72 billion, a price-to-earnings ratio of 57.63, a price-to-earnings-growth ratio of 12.93 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 6,906 shares of company stock worth $1,265,855. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.